Average cost of drugs for extensively drug-resistant tuberculosis in Myanmar
Myanmar: Average cost of drugs for extensively drug-resistant tuberculosis was 963 constant 2022 US$ in 2024. ◆ Volatile
Average cost of drugs for extensively drug-resistant tuberculosis in Myanmar, 2017–2024
Source: WHO (2025) – with minor processing by Our World in Data. Measured in constant 2022 US$.
Analysis
Myanmar recorded 963 constant 2022 US$ for average cost of drugs for extensively drug-resistant tuberculosis in 2024. That is the lowest value across all 8 years on record.
Compared with earlier readings it is down 48.9% on the previous year and down 89.6% over ten years.
Myanmar ranks 43rd of 56 countries on this measure, in the bottom quarter.
Average cost of drugs for extensively drug-resistant tuberculosis in Myanmar, year by year
| Year | constant 2022 US$ | Change |
|---|---|---|
| 2017 | 9,230 constant 2022 US$ | — |
| 2018 | 9,230 constant 2022 US$ | +0.0% |
| 2019 | 4,431 constant 2022 US$ | -52.0% |
| 2020 | 4,431 constant 2022 US$ | +0.0% |
| 2021 | 3,082 constant 2022 US$ | -30.4% |
| 2022 | 3,082 constant 2022 US$ | +0.0% |
| 2023 | 1,885 constant 2022 US$ | -38.8% |
| 2024 | 963 constant 2022 US$ | -48.9% |
Myanmar compared with similar countries
- Myanmar's 963 constant 2022 US$ is below the median for lower middle income countries, which is 1,525 constant 2022 US$, 63% of the median. (24 countries reporting)
- Myanmar's 963 constant 2022 US$ is below the median for East Asia & Pacific, which is 1,194 constant 2022 US$, 81% of the median. (8 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 7,630 constant 2022 US$ | 4,431 constant 2022 US$ | 9,230 constant 2022 US$ | 3 |
| 2020s | 2,689 constant 2022 US$ | 963 constant 2022 US$ | 4,431 constant 2022 US$ | 5 |
Countries ranked near Myanmar
More reference data data for Myanmar
- Emission Totals - Indirect emissions (N2O) - Manure applied to Soils 3.28 (2050)
- Emission Totals - Indirect emissions (N2O) - Manure left on Pasture 4.58 (2050)
- Emission Totals - Indirect emissions (N2O) - IPCC Agriculture 11.17 (2050)
- Emission Totals - Indirect emissions (N2O) - Crop Residues 2.53 (2050)
- Emission Totals - Indirect emissions (N2O) - Agricultural Soils 11.17 (2050)
- Emission Totals - Emissions (N2O) - Manure applied to Soils 11.01 (2050)
- Emission Totals - Emissions (N2O) - Manure Management 19.7 (2050)
- Emission Totals - Emissions (N2O) - Manure left on Pasture 25.14 (2050)
- Emission Totals - Emissions (N2O) - IPCC Agriculture 73.24 (2050)
- Emission Totals - Emissions (N2O) - Crop Residues 13.8 (2050)
Frequently asked questions
- What is average cost of drugs for extensively drug-resistant tuberculosis in Myanmar?
- Average cost of drugs for extensively drug-resistant tuberculosis in Myanmar was 963 constant 2022 US$ in 2024, according to WHO (2025) – with minor processing by Our World in Data.
- What is the highest average cost of drugs for extensively drug-resistant tuberculosis recorded in Myanmar?
- The highest recorded value was 9,230 constant 2022 US$ in 2017.
- What is the lowest average cost of drugs for extensively drug-resistant tuberculosis recorded in Myanmar?
- The lowest recorded value was 963 constant 2022 US$ in 2024.
- How does Myanmar rank for average cost of drugs for extensively drug-resistant tuberculosis?
- Myanmar ranks 43rd out of 56 countries with data for 2024.
- Is average cost of drugs for extensively drug-resistant tuberculosis rising or falling in Myanmar?
- Over the last ten years it is down 89.6%. The long-run trend across the full record is volatile.
- Where does this Myanmar data come from?
- The figures come from WHO (2025) – with minor processing by Our World in Data, published as part of Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 8 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.